.Pharmacolibrary.Drugs.ATC.N.N07BC01 .Pharmacolibrary.Drugs.ATC.N.N07BC01| name: | Buprenorphine |
| ATC code: | N07BC01 | route: | sublingual |
| n-compartments | 2 |
Buprenorphine is a semi-synthetic opioid used primarily in the treatment of opioid dependence and chronic pain. It is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is approved for use in opioid substitution therapy and is available in multiple formulations including sublingual tablets, subcutaneous injection, and transdermal patches.
Pharmacokinetic parameters reported for healthy adult subjects, mixed sex, after single sublingual administration.
Gu, M, et al., & Zhu, X (2023). Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. Frontiers in pharmacology 14 1089862–None. DOI:10.3389/fphar.2023.1089862 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36744255
Ng, CM, et al., & Kraft, WK (2015). Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy 35(7) 670–680. DOI:10.1002/phar.1610 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26172282
Jones, AK, et al., & Laffont, CM (2021). Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials. Clinical pharmacokinetics 60(4) 527–540. DOI:10.1007/s40262-020-00957-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33135125